Advanced search
Publication Cover
Infectious Diseases Volume 55, 2023 - Issue 9
Submit an article Journal homepage
1,507
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints

Burcu Islera UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia;b Infection Management Services, Princess Alexandra Hospital, Brisbane, AustraliaCorrespondence[email protected]
View further author information
,
Cansel Vatanseverc Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, TurkeyView further author information
,
Berna Özerc Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, TurkeyView further author information
,
Güle Çınard Infectious Diseases and Clinical Microbiology, School of Medicine, Ankara UniversityAnkara, TurkeyView further author information
,
Abdullah Tarık Aslane Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
,
Caitlin Falconera UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, AustraliaView further author information
,
Michelle J. Bauera UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, AustraliaView further author information
,
Brian Fordea UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, AustraliaView further author information
,
Funda Şimşekf Infectious Diseases and Clinical Microbiology, University of Health Sciences, Ministry of Health Prof Dr Cemil Taşçıoğlu City Hospital, Istanbul, TurkeyView further author information
,
Necla Tülekg Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Atilim University, Ankara, TurkeyView further author information
,
Hamiyet Demirkayah Infectious Diseases and Clinical Microbiology, Ankara Hospital, Başkent University, Ankara, TurkeyView further author information
,
Şirin Menekşei Infectious Diseases, Koşuyolu Kartal Heart Training and Research Hospital, Istanbul, TurkeyView further author information
,
Halis Akalinj Infectious Diseases and Clinical Microbiology, School of Medicine, Uludağ University, Bursa, TurkeyView further author information
,
İlker İnanç Balkank Infectious Diseases and Clinical Microbiology, School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, TurkeyView further author information
,
Mehtap Aydınl Infectious Diseases and Clinical Microbiology, Ümraniye Training and Research Hospital, University of Health Sciences, Istanbul, TurkeyView further author information
,
Elif Tükenmez Tigenm Infectious Diseases and Clinical Microbiology, Pendik Training and Research Hospital, Marmara University, Istanbul, TurkeyView further author information
,
Safiye Koçulu Demirn Infectious Diseases and Clinical Microbiology, Demiroglu Bilim University, Istanbul, TurkeyView further author information
,
Mahir Kapmazo Infectious Diseases and Clinical Microbiology, Koç University Hospital, Istanbul, TurkeyView further author information
,
Şiran Keskec Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey;p Infectious Diseases, VKV American Hospital, Istanbul, TurkeyView further author information
,
Özlem Doğanc Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, TurkeyView further author information
,
Çiğdem Arabacıq Clinical Microbiology, Ministry of Health Prof Dr Cemil Taşçıoğlu City Hospital, University of Health Sciences, Istanbul, TurkeyView further author information
,
Serap Yağcır Clinical Microbiology, Ankara Training and Research Hospital, Ankara, TurkeyView further author information
,
Gülşen Hazırolans Clinical Microbiology, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
,
Veli Oğuzalp Bakırt Graduate School of Sciences and Engineering, Koç University, Istanbul, TurkeyView further author information
,
Mehmet Gönenu Industrial Engineering, College of Engineering, Koç University, Istanbul, TurkeyView further author information
,
Neşe Saltoğluk Infectious Diseases and Clinical Microbiology, School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, TurkeyView further author information
,
Alpay Azapd Infectious Diseases and Clinical Microbiology, School of Medicine, Ankara UniversityAnkara, TurkeyView further author information
,
Özlem Azaph Infectious Diseases and Clinical Microbiology, Ankara Hospital, Başkent University, Ankara, TurkeyView further author information
,
Murat Akovae Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
,
Önder Ergönülc Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey;v Koç University İş Bank Centre for Infectious Diseases (KUISCID), Istanbul, TurkeyView further author information
,
Füsun Canc Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey;v Koç University İş Bank Centre for Infectious Diseases (KUISCID), Istanbul, TurkeyView further author information
,
David L. Patersona UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, AustraliaView further author information
&
Patrick N. A. Harrisa UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, AustraliaView further author information
 show all
Pages 607-613 | Received 16 Dec 2022, Accepted 14 Jun 2023, Published online: 30 Jun 2023

References

  • Isler B, Aslan AT, Akova M, et al. Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections. Expert Rev Anti Infect Ther. 2022;20(11):1389–1400. doi:10.1080/14787210.2022.2128764.
  • Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 study). Int J Antimicrob Agents. 2019;53(2):177–184. doi:10.1016/j.ijantimicag.2018.10.007.
  • Kohira N, Hackel MA, Ishioka Y, et al. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist. 2020;22:738–741. doi:10.1016/j.jgar.2020.07.009.
  • Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240. doi:10.1016/S1473-3099(20)30796-9.
  • Morris CP, Bergman Y, Tekle T, et al. Cefiderocol antimicrobial susceptibility testing against Multidrug-Resistant Gram-Negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol. 2020;59(1):e01649-20. doi:10.1128/JCM.01649-20.
  • Matuschek E, Longshaw C, Takemura M, et al. Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing. J Antimicrob Chemother. 2022;77(6):1662–1669. doi:10.1093/jac/dkac080.
  • European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters, version 11.0. 2021. [accessed 2022 Feb 10]. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf
  • Clinical and laboratory standards institute (CLSI). M100-ED31. Performance Standards for Antimicrobial Susceptibility Testing, 31st ed. Table 2A. Zone Diameter and MIC Breakpoints for Enterobacterales. 2021.
  • Isler B, Özer B, Çınar G, et al. Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting. Eur J Clin Microbiol Infect Dis. 2022;41(5):841–847. doi:10.1007/s10096-022-04425-4.
  • Feldgarden M, Brover V, Haft DH, et al. Validating the AMRFinder tool and resistance gene database by using antimicrobial resistance Genotype-Phenotype correlations in a collection of isolates. Antimicrob Agents Chemother. 2019;63(11):e00483-19. doi:10.1128/AAC.00483-19.
  • Simner PJ, Mostafa HH, Bergman Y, et al. Progressive development of cefiderocol resistance in Escherichia coli during therapy is associated with increased blaNDM-5 copy number and gene expression. Clin Infect Dis. 2021;75:47–54.
  • Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-Negative bacteria. Antimicrob Agents Chemother. 2018;62(1):e01454-17. doi:10.1128/AAC.01454-17.
  • Yamano Y, Takemura M, Nakamura R, et al. Frequency of resistance acquisition and resistance mechanisms to cefiderocol. Presented at: ID Week Annual Meeting; 2020 October 22–25; Online conference; Poster 1455.
  • Kawai A, McElheny CL, Iovleva A, et al. Structural basis of reduced susceptibility to Ceftazidime-Avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion. Antimicrob Agents Chemother. 2020;64(7):e00198-20. doi:10.1128/AAC.00198-20.
  • Shields RK, Iovleva A, Kline EG, et al. Clinical evolution of AmpC-Mediated Ceftazidime-Avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime. Clin Infect Dis. 2020;71(10):2713–2716. doi:10.1093/cid/ciaa355.
  • Katsube T, Echols R, Wajima T. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. Clin Infect Dis. 2019;69(7):S552–S558. doi:10.1093/cid/ciz828.
  • Tan X, Kim HS, Baugh K, et al. Therapeutic options for metallo-β-Lactamase-Producing enterobacterales. Infect Drug Resist. 2021;14:125–142. doi:10.2147/IDR.S246174.
  • Timsit JF, Paul M, Shields RK, et al. Cefiderocol for the treatment of infections due to Metallo-Beta-Lactamase-Producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies. Clin Infect Dis. 2022;75:1081–1084.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.